Volume 42 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
ZHANG Jingsui, YANG Po, REHEMAN Alimu, HE Enpeng. Research update on the effect of irisin/FNDC5 on metabolism of children and adolescents[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(8): 1270-1274. doi: 10.16835/j.cnki.1000-9817.2021.08.034
Citation: ZHANG Jingsui, YANG Po, REHEMAN Alimu, HE Enpeng. Research update on the effect of irisin/FNDC5 on metabolism of children and adolescents[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(8): 1270-1274. doi: 10.16835/j.cnki.1000-9817.2021.08.034

Research update on the effect of irisin/FNDC5 on metabolism of children and adolescents

doi: 10.16835/j.cnki.1000-9817.2021.08.034
  • Received Date: 2020-11-28
  • Rev Recd Date: 2021-01-20
  • Available Online: 2021-08-20
  • Publish Date: 2021-08-25
  • The metabolic level of children and adolescents is of great significance in the healthy growth and development of children and adolescents. Irisin, as a myokine, was first discovered and named in 2012. Early studies showed that irisin can participate in body metabolism and inhibit the occurrence of obesity. Later studies found that irisin can improve the symptoms of type 2 diabetes mellitus, metabolic syndrome, osteoporosis and other diseases. At the same time, irisin can promote glucose, lipid metabolism and bone metabolism in children and adolescents, and its mechanism is still controversial. In this review, research update regarding the effect of irisin/FNDC5 on metabolism (lipid metabolism, glucose metabolism, bone metabolism) in children and adolescents were summarized in order to provide theoretical reference for researchers in the field of the metabolism of children and adolescents.
  • loading
  • [1]
    冯俊鹏, 严翊. 国内外儿童、青少年体力活动现状分析: 基于2018年《全球儿童、青少年体力活动报告》[J]. 中国运动医学杂志, 2019, 38(12): 1094-1100. doi: 10.3969/j.issn.1000-6710.2019.12.013

    FENG J P, YAN Y. Analysis on the current situation of physical activity of children and adolescents at home and abroad: based on the 2018 global report on physical activity of children and adolescents[J]. Chin J Sports Med, 2019, 38(12): 1094-1100. doi: 10.3969/j.issn.1000-6710.2019.12.013
    MCLOUGHLIN G M, BAI Y, WELK G J. Longitudinal associations between physical fitness and academic achievement in youth[J]. Med Sci Sports Exerc, 2020, 52(3): 616-622. doi: 10.1249/MSS.0000000000002159
    BOSTRM P, WU J, JEDRYCHOWSKI M P, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J]. Nature, 2012, 481(7382): 463-468. doi: 10.1038/nature10777
    AYDIN S, KULOGLU T, AYDIN S, et al. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle[J]. Peptides, 2014, 52(2): 68-73. http://smartsearch.nstl.gov.cn/paper_detail.html?id=884fef0063f56b040545a0e3f525c1eb
    AYDIN S, KULOGLU T, YILMAZ M, et al. Alterations of Irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45 min of a Turkish bath or running[J]. Peptides, 2013, 50(complete): 13-18. http://europepmc.org/abstract/med/24096106
    HECKSTEDEN A, WEGMANN M, STEFFEN A, et al. Irisin and exercise training in humans-results from a randomized controlled training trial[J]. BMC Med, 2013, 11(1): 235. doi: 10.1186/1741-7015-11-235
    GOUVEIA M C, VELLA J P, CAFEO F K, et al. Association between irisin and major chronic disease: a review[J]. Eur Rev Med Pharmacol Sci, 2016, 20(19): 4072-4077. http://www.ncbi.nlm.nih.gov/pubmed/27775791
    POLYZOS S A, ANASTASILAKIS A D, EFSTATHIADOU Z A, et al. Irisin in metabolic diseases[J]. Endocrine, 2018, 59(2): 260-274. doi: 10.1007/s12020-017-1476-1
    PERAKAKIS N, TRIANTAFYLLOU G A, FERNÁNDEZ-REAL J M, et al. Physiology and role of Irisin in glucose homeostasis[J]. Nat Rev Endocrinol, 2017, 13(6): 324-337. doi: 10.1038/nrendo.2016.221
    REILLY J J, KELLY J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review[J]. Int J Obes, 2011, 35(Suppl 4): 891-898. http://www.bmj.com/lookup/external-ref?access_num=20975725&link_type=MED&atom=%2Fbmj%2F346%2Fbmj.f3092.atom
    JANG H B, KIM H J, KANG J H, et al. Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents[J]. Metabolism, 2017, 73(8): 100-108. http://www.ncbi.nlm.nih.gov/pubmed/28732566
    HEE P, ZAICHENKO L, BRINKOETTER M, et al. Circulating Irisin in relation to insulin resistance and the metabolic syndrome[J]. J Clin Endocrinol Metab, 2013, 98(12): 4899-4907. doi: 10.1210/jc.2013-2373
    PYRAK B, DEMKOW U, KUCHARSKA A M. Brown adipose tissue and browning agents: Irisin and FGF21 in the development of obesity in children and adolescents[M]. Cham: Springer, 2015: 25-34.
    LETICIA E M, CHRISTIAN S P, ALEJANDRO T Q, et al. Association of Irisin plasma levels with anthropometric parameters in children with underweight, normal weight, overweight, and obesity[J]. Bio Med Res Int, 2017, 2017(5-3): 2628968. http://europepmc.org/articles/PMC5434279/
    PALACIOS-GONZÁLEZ B, VADILLO-ORTEGA F, POLO-OTEYZA E, et al. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin[J]. Obesity, 2015, 23(4): 729-732. doi: 10.1002/oby.21029
    GONZALEZ-GIL A M, PESCHARD-FRANCO M, CASTILLO E C, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome[J]. Diabetol Metab Syndr, 2019, 11(1): 63. doi: 10.1186/s13098-019-0458-2
    SHIM Y S, KANG M J, YANG S, et al. Irisin is a biomarker for metabolic syndrome in prepubertal children[J]. Endocr J, 2018, 65(1): 23-31. doi: 10.1507/endocrj.EJ17-0260
    ELIZONDO-MONTEMAYOR L, GONZALEZ-GIL A M, TAMEZ-RIVERA O, et al. Association between Irisin, hs-CRP, and metabolic status in children and adolescents with type 2 diabetes mellitus[J]. Mediators Inflamm, 2019, 2019: 6737318.
    YIN C, HU W, WANG M, et al. Irisin as a mediator between obesity and vascular inflammation in Chinese children and adolescents[J]. Nutr Metab Cardiovasc Dis, 2020, 30(2): 320-329. doi: 10.1016/j.numecd.2019.09.025
    BLVHER S, PANAGIOTOU G, PETROFF D, et al. Effects of a 1-year exercise and lifestyle intervention on Irisin, adipokines, and inflammatory markers in obese children[J]. Obesity, 2014, 22(7): 1701-1708. doi: 10.1002/oby.20739
    REINEHR T, ELFERS C, LASS N, et al. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis[J]. J Clin Endocrinol Metab, 2015, 100(5): 2123-2130. doi: 10.1210/jc.2015-1208
    KARAMPATSOU S I, GENITSARIDI S M, PAPAGEORGIOU I, et al. The role of fibroblast growth factor 21 and Irisin in the pathogenesis of obesity in childhood and adolescence[C]//Hormone Research in Paediatrics. Allschwilerstrasse 10, CH-4009 Basel, Switzerland: Karger, 2018: 323.
    VⅡTASALO A, GREN J, VENLINEN T, et al. Association of plasma fatty acid composition with plasma Irisin levels in normal weight and overweight/obese children[J]. Pediatr Obes, 2016, 11(4): 299-305. doi: 10.1111/ijpo.12062
    SEPP S, TENHOLA S, VOUTILAINEN R. Fibroblast Growth Factor 21, Adiponectin, and Irisin as markers of unfavorable metabolic features in 12-year-old children[J]. J Endocr Soc, 2019, 3(4): 825-837. doi: 10.1210/js.2018-00399
    NIGRO E, SCUDIERO O, MONACO M L, et al. Adiponectin profile and Irisin expression in Italian obese children: association with insulin-resistance[J]. Cytokine, 2017, 94(6): 8-13. http://www.sciencedirect.com/science/article/pii/S1043466616306044
    AL-DAGHRI N M, ALKHARFY K M, RAHMAN S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects[J]. Eur J Clin Invest, 2014, 44(2): 119-124. doi: 10.1111/eci.12196
    WU J, BOSTRM P, SPARKS L M, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human[J]. Cell, 2012, 150(2): 366-376. doi: 10.1016/j.cell.2012.05.016
    IRVING B A, STILL C D, ARGYROPOULOS G. Does IRISIN have a BRITE future as a therapeutic agent in humans?[J]. Curr Obes Rep, 2014, 3(2): 235-241. doi: 10.1007/s13679-014-0091-1
    NIRANJAN S B, BELWALKAR S V, TAMBE S, et al. Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis[J]. Biochem Biophys Res Commun, 2019, 519(2): 422-429. doi: 10.1016/j.bbrc.2019.08.112
    TSAI Y C, WANG C W, WEN B Y, et al. Involvement of the p62/Nrf2/HO-1 pathway in the browning effect of irisin in 3T3-L1 adipocytes[J]. Mol Cell Endocrinol, 2020, 514(8): 110915.
    LI H, ZHANG Y, WANG F, et al. Original Article Effects of irisin on the differentiation and browning of human visceral white adipocytes[J]. Am J Transl Res, 2019, 11(12): 7410-7421. http://www.ncbi.nlm.nih.gov/pubmed/31934288
    HUH J Y, DINCER F, MESFUM E, et al. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J]. Int J Obes, 2014, 38(12): 1538-1544. doi: 10.1038/ijo.2014.42
    SESTI G, ANDREOZZI F, FIORENTINO T V, et al. High circulating Irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects[J]. Acta Diabetolog, 2014, 51(5): 705-713. doi: 10.1007/s00592-014-0576-0
    CHEN N, LI Q, LIU J, et al. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review[J]. Diabet Metab Res Rev, 2016, 32(1): 51-59. doi: 10.1002/dmrr.2660
    MORENO N, FRANCISCO O, MARTA S, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance[J]. J Clin Endocrinol Metab, 2013, 98(4): E769-E778. doi: 10.1210/jc.2012-2749
    LIU T Y, SHI C X, GAO R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes[J]. Clin Sci, 2015, 129(10): 839-850. doi: 10.1042/CS20150009
    HUANG L, YAN S, LUO L, et al. Irisin regulates the expression of BDNF and glycometabolism in diabetic rats[J]. Mol Med Rep, 2019, 19(2): 1074-1082. http://www.ncbi.nlm.nih.gov/pubmed/30569121
    HUH J Y, PANAGIOTOU G, MOUGIOS V, et al. FNDC5 and Irisin in humans: I. Predictors of circulating concentrations in serum and plasma and Ⅱ. mRNA expression and circulating concentrations in response to weight loss and exercise[J]. Metabolism, 2012, 61(12): 1725-1738. doi: 10.1016/j.metabol.2012.09.002
    PANG Y, ZHU H, XU J, et al. β-arrestin-2 is involved in Irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling[J]. Exp Cell Res, 2017, 360(2): 199-204. doi: 10.1016/j.yexcr.2017.09.006
    TANG H, YU R, LIU S, et al. Irisin inhibits hepatic cholesterol synthesis via AMPK-SREBP2 signaling[J]. EbioMedicine, 2016, 6: 139-148. doi: 10.1016/j.ebiom.2016.02.041
    LIU T Y, SHI C X, GAO R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes[J]. Clin Sci, 2015, 129(10): 839-850. doi: 10.1042/CS20150009
    ZHOU Q, CHEN K, LIU P, et al. Dihydromyricetin stimulates irisin secretion partially via the PGC-1α pathway[J]. Mol Cell Endocrinol, 2015, 412(9): 349-357. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-EGYN201505001366.htm
    ZHANG Y, LI R, MENG Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling[J]. Diabetes, 2014, 63(2): 514-525. doi: 10.2337/db13-1106
    LOOMBA-ALBRECHT L A, STYNE D M. Effect of puberty on body composition[J]. Curr Opin Endocrinol Diabet Obes, 2009, 16(1): 10-15. doi: 10.1097/MED.0b013e328320d54c
    SOPHER A B, FENNOY I, OBERFIELD S E. An update on childhood bone health: mineral accrual, assessment and treatment[J]. Curr Opin Endocrinol Diabet Obes, 2015, 22(1): 35-40. doi: 10.1097/MED.0000000000000124
    SOININEN S, SIDOROFF V, LINDI V, et al. Body fat mass, lean body mass and associated biomarkers as determinants of bone mineral density in children 6-8 years of age-The Physical Activity and Nutrition in Children (PANIC) study[J]. Bone, 2018, 108(3): 106-114. http://www.sciencedirect.com/science/article/pii/S8756328218300036
    COLAIANNI G, FAIENZA M F, SANESI L, et al. Irisin serum levels are positively correlated with bone mineral status in a population of healthy children[J]. Pediatr Res, 2019, 85(4): 484-488. doi: 10.1038/s41390-019-0278-y
    FAIENZA M F, BRUNETTI G, SANESI L, et al. High Irisin levels are associated with better glycemic control and bone health in children with type 1 diabetes[J]. Diabet Res Clin Pract, 2018, 141(7): 10-17. http://d.wanfangdata.com.cn/periodical/e8f97e336858623b7bafc3c3185285a1
    GRANO M, COLAIANNI G, CUSCITO C, et al. Irisin for care and prevention of osteoporosis: U.S. 15/098, 418[P]. 2017-02-02.
    ZHOU K, QIAO X, CAI Y, et al. Lower circulating Irisin in middle-aged and older adults with osteoporosis: a systematic review and meta-analysis[J]. Menopause, 2019, 26(11): 1302-1310. doi: 10.1097/GME.0000000000001388
    WU L F, ZHU D C, TANG C H, et al. Association of plasma Irisin with bone mineral density in a large chinese population using an extreme sampling design[J]. Calcif Tissue Int, 2018, 103(3): 246-251. doi: 10.1007/s00223-018-0415-3
    BONFANTE I L P, CHACON-MIKAHIL M P T, BRUNELLI D T, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk[J]. Arch Endocrinol Metab, 2017, 61(6): 524-533. doi: 10.1590/2359-3997000000305
    COLAIANNI G, CUSCITO C, MONGELLI T, et al. Irisin enhances osteoblast differentiation in vitro[J]. Int J Endocrinol, 2014(2014): 902186. http://www.ncbi.nlm.nih.gov/pubmed/24723951
    田梦婷, 刘晶, 曾雪敏, 等. 鸢尾素对大鼠骨髓间充质干细胞Sost基因表达及成骨分化的影响[J]. 中华口腔医学研究杂志(电子版), 2019, 13(3): 144-150. doi: 10.3877/cma.j.issn.1674-1366.2019.03.003

    TIAN M T, LIU J, ZENG X M, et al. Effect of Irisin on osteogenic differentiation and Sost of rat bone marrow mesenchymal stem cells[J]. Chin J Stomatol Res (Elect Ed), 2019, 13(3): 144-150. doi: 10.3877/cma.j.issn.1674-1366.2019.03.003
    MA Y, QIAO X, ZENG R, et al. Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells[J]. Faseb J, 2018, 32(11): 5813-5823. doi: 10.1096/fj.201700983RR
    COLAIANNI G, NOTARNICOLA A, SANESI L, et al. Irisin levels correlate with bone mineral density in soccer players[J]. J Biol Regul Homeostat Agents, 2017, 31(Suppl 1): 21-28. http://www.ncbi.nlm.nih.gov/pubmed/29181953
    METZGER C E, NARAYANAN S A, ELIZONDO J P, et al. DSS-induced colitis produces inflammation-induced bone loss while Irisin treatment mitigates the inflammatory state in both gut and bone[J]. Sci Rep, 2019, 9(1): 423-439. doi: 10.1038/s41598-018-36714-4
    QIAO X, NIE Y, MA Y, et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways[J]. Sci Rep, 2016, 6(1): 817-831. http://europepmc.org/articles/PMC4704023/
    STORLINO G, COLAIANNI G, SANESI L, et al. Irisin prevents disuse-induced osteocyte apoptosis[J]. J Bone Miner Res, 2020, 35(4): 766-775. doi: 10.1002/jbmr.3944
    WANG F S, KUO C W, KO J Y, et al. Irisin mitigates oxidative stress, chondrocyte dysfunction and osteoarthritis development through regulating mitochondrial integrity and autophagy[J]. Antioxidants, 2020, 9(9): 810. doi: 10.3390/antiox9090810
    CHEN X, SUN K, ZHAO S, et al. Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt//β-catenin signal pathway[J]. Cytokine, 2020, 136(12): 155292. http://www.sciencedirect.com/science/article/pii/S1043466620303082
    HE Z, LI H, HAN X, et al. Irisin inhibits osteocyte apoptosis by activating the Erk signaling pathway in vitro and attenuates ALCT-induced osteoarthritis in mice[J]. Bone, 2020, 141(12): 115573.
    COLAIANNI G, SANESI L, STORLINO G, et al. Irisin and bone: From preclinical studies to the evaluation of its circulating levels in different populations of human subjects[J]. Cells, 2019, 8(5): 451. doi: 10.3390/cells8050451
    COLAIANNI G, CUSCITO C, MONGELLI T, et al. The myokine irisin increases cortical bone mass[J]. Proc Natl Acad Sci, 2015, 112(39): 12157-12162. doi: 10.1073/pnas.1516622112
    ZHANG J, VALVERDE P, ZHU X, et al. Exercise-induced Irisin in bone and systemic Irisin administration reveal new regulatory mechanisms of bone metabolism[J]. Bone Res, 2017, 5(1): 49-62. http://d.wanfangdata.com.cn/Periodical_gyj-e201701005.aspx
    KANG Y S, KIM J C, KIM J S, et al. Effects of swimming exercise on serum irisin and bone FNDC5 in rat models of high-fat diet-induced osteoporosis[J]. J Sport Sci Med, 2019, 18(4): 596-603. http://www.ncbi.nlm.nih.gov/pubmed/31827343
    VIBHA S, LAWSON E A, ACKERMAN K E, et al. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates[J]. PLoS One, 2014, 9(6): e100218. doi: 10.1371/journal.pone.0100218
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (657) PDF downloads(43) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint